NR4A1 and breast carcinoma: Although two prior studies suggested that HER2-low positivity may be less likely in those with ILC [8, 9], the prevalence of HER2-low status in our cohort is similar to what is reported in hormone receptor positive breast cancer, irrespective of histology [1, 8, 16].